BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
Clinical - Phase II
Biocryst Pharmaceuticals (BCRX) Receives Orphan Drug Designation For BCX4161 For The Treatment Of Hereditary Angioedema 12/24/2014
Achillion Pharmaceuticals, Inc. (ACHN) Surges as Potential Drug Combo Seen as Hepatitis C Cure 12/23/2014
NeuroLifeSciences Release: Redefining ADHD: A New Approach & A Shift Of Paradigm In ADHD Therapeutics 12/23/2014
Provectus Biopharmaceuticals Inc.’ Protocol For Phase 2 Study Of Mechanism Of Action Of PH-10 On Immunologic Makers Of Psoriasis Now Available Online 12/23/2014
BioTie Therapies Corp. Announces Start Of Syn120 Phase 2a Trial In Parkinson's Disease Dementia And Provides Outlook Update For Near Term Pipeline Events 12/23/2014
Cellceutix (CTIX) Reports Positive Results Of Brilacidin In Microbiological Intent-To-Treat Population In Phase 2b ABSSSI Trial; Additional Pharmacokinetic Information To Be Submitted 12/23/2014
Five Quick Takes on Stem Cells: CIRM, Sanford-Burnham Medical, BioWorld, StemCells (STEM), Cellular Dynamics 12/23/2014
Achillion Pharmaceuticals, Inc. (ACHN) Shows Potential For "Best-In-Disease" HCV Regimen - 100% SVR4 Following A Dual 6-Week ACH-3102-Based Regimen And Separately A 4.8 Log10 Reduction With ACH-3422 12/22/2014
VBL Therapeutics (VBLX) Announces Positive Phase 2a Data For VB-111 In Recurrent Thyroid Cancer 12/22/2014
FDA Grants Orphan Drug Designation To Nuvilex (NVLX) For Pancreatic Cancer Treatment 12/22/2014
Can-Fite BioPharma (CFBI) Doses First Patient In Global Phase 2 Liver Cancer Trial For CF102 12/22/2014
Eiger Bio Announces Positive Data In Patients Infected With Hepatitis Delta Virus (HDV) Treated With Lonafarnib - Results Presented At American Association for Study of Liver Diseases Meeting 12/22/2014
MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) (MSHL) Reaches Response Milestone In Phase 2 Clinical Trial Of Pracinostat In Refractory Myelodysplastic Syndrome 12/22/2014
MediGene AG (MDGEF.PK) Receives Clinical Trial Approval For Phase I/II Study With DC Vaccine To Treat Acute Myeloid Leukaemia (AML) 12/22/2014
Cerus Corporation (CERS) Reports U.S. Phase 2 Clinical Trial Of INTERCEPT Red Blood Cells Met Primary Endpoint 12/22/2014
Second Phase Of GlaxoSmithKline (GSK)'s Ebola Vaccine Delayed 12/22/2014
Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Receives Orphan Drug Designation In The United States And The European Union For The Treatment Of Malignant Pleural Mesothelioma 12/19/2014
AB Science (AB.PA): Report Of Positive Clinical Study Data In Metastatic Colorectal Cancer 12/19/2014
Innate Pharma (IPH.PA ): First Phase 2 Trial With IPH2201 Open In Head And Neck Cancer 12/19/2014
Amarantus BioSciences, Inc. Submits Orphan Drug Designation Application To U.S. FDA For Treatment Of Retinal Artery Occlusion With Product Candidate MANF 12/19/2014
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Results From The Phase 2 Borealis-1 Trial Of Apatorsen In The Treatment Of Metastatic Bladder Cancer 12/19/2014
Halozyme Therapeutics, Inc. (HALO) Receives European Orphan Drug Designation For PEGylated Recombinant Human Hyaluronidase PH20 For Pancreatic Cancer 12/19/2014
Xenetic Biosciences Completes Enrollment Of Second Cohort In Phase 2a Study With Erepoxen® For Anemia; Hemoglobin Levels Rise Into Therapeutic Range Over Time 12/19/2014
TetraLogic Pharmaceuticals (TLOG) Announces Initiation Of A Randomized Phase 2 Clinical Trial Of SHAPE In Subjects With Cutaneous T-Cell Lymphoma 12/18/2014
Fate Therapeutics (FATE) Announces Interim Data From Ongoing Phase 2 PUMA Study 12/18/2014
Biocryst Pharmaceuticals (BCRX) Initiates Opus-2: A Clinical Trial Of BCX4161 In Patients With Hereditary Angioedema 12/18/2014
StemCells Inc. (STEM) Transplants First Participant In Phase 2 Clinical Trial In Cervical Spinal Cord Injury 12/18/2014
Nuvo Research Inc. (NRI.TO) Reports That All Patients Have Completed Phase 2 Study Of WF10 For The Treatment Of Allergic Rhinitis 12/18/2014
D-Pharm Ltd. Achieves Primary End-Point In Phase 2 Clinical Study Of THR-18 In Acute Stroke Patients Treated With tPA 12/18/2014
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Release: Study Further Validates Cell Therapy Approach To Reverse Type 1 Diabetes 12/18/2014
Ablynx (ABLYF) Opens Recruitment For First-In-Infant Phase 2a Study With Its Anti-Rsv Nanobody, ALX-0171 12/17/2014
Stemline Therapeutics, Inc. (STML) Initiates SL-401 Clinical Trial In Four Rare Myeloproliferative Neoplasms 12/17/2014
RXi Pharmaceuticals (RXII) Announces Sustained Effect Of RXI-109 At Three Months Post Scar Revision Surgery And The Completion Of Enrollment For Its Phase 2a Trial RXI-109-1301 12/17/2014
Pfizer (PFE) Initiates Phase 2 Study Of PF-06252616 In Duchenne Muscular Dystrophy 12/17/2014
Pivotal Therapeutics Inc. Release: VASCAZEN POMEGA Phase 2a Trial Protocol Cleared Clinical Evaluation By French FDA 12/17/2014
Velocity Pharmaceutical Development And Tigercat Pharma, Inc. Announce Phase 2 Results For VPD-737 In Patients With Chronic Pruritus 12/17/2014
First Patient Treated In Mapi Pharma's Phase 2a Clinical Trial Of GA Depot For Relapsing Remitting Multiple Sclerosis (RRMS) 12/17/2014
Poxel Announces Positive Top Line Results For Its Antidiabetic Agent Imeglimin In A Phase 2b Dose-Ranging Trial 12/17/2014
Neovacs SA Announces Top Line Phase 2b Clinical Trial Results Of TNF-Kinoid In Rheumatoid Arthritis And Update On Clinical Programs 12/16/2014
Anavex Life Sciences Corp. (AVXL.OB) Begins Enrollment Of Alzheimer's Patients In Phase 2a Clinical Trial Of ANAVEX 2-73 And ANAVEX PLUS 12/16/2014
Galapagos NV (GLPG.BR) Regains Full Rights To GPR84 Inhibitor GLPG1205 12/16/2014
GENFIT Corp. (ALGFT): Gft505 Treatment Prevents Evolution To Cirrhosis 12/16/2014
SOV Therapeutics Announces Successful Phase 2b Study Of Oral Testosterone Undecanoate For Treatment Of Primary And Secondary Hypogonadism In Adult Males 12/16/2014
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 1/2 Study Of ISIS-DMPK Rx In Patients With Myotonic Dystrophy Type 1 12/16/2014
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Completion Of Patient Enrollment In The Rainier™ Clinical Trial Evaluating Apatorsen In Combination With ABRAXANEв Plus Gemcitabine In Patients With Metastatic Pancreatic Cancer 12/16/2014
Bone Therapeutics Confirms Safety In ALLOB® Phase 1/2a Trial For Delayed-Union Fractures 12/16/2014
Why Gilead Sciences, Inc. (GILD) And AbbVie (ABBV) Are Keeping An Eye On Achillion Pharmaceuticals, Inc. (ACHN) 12/15/2014
VBL Therapeutics (VBLX) Announces Last Patient Out In Phase 2 Clinical Studies Of VB-201 In Psoriasis And Ulcerative Colitis 12/15/2014
Zafgen (ZFGN) Announces Initiation Of Phase 2b Trial Of Beloranib In Severe Obesity 12/15/2014
Araim Pharmaeuticals Release: New Study Published In Molecular Medicine Reports That Novel Agent Decreases Neuropathic Pain In Patients With Type 2 Diabetes 12/15/2014
Ascendis Pharma A/S Announces Positive Six-Month Interim Results From A Phase 2 Pediatric Study Of Once-Weekly Transcon Growth Hormone For The Treatment Of Growth Hormone Deficiency 12/15/2014
Can-Fite BioPharma (CFBI) Release: Second Part Of The Glaucoma Phase 2 Study Has Been Approved In A European Country 12/15/2014
Taiwan's TWi Biotech To Start Clinical Trial Of Gout Treatment 12/15/2014
Vaxil Publishes The Results Of Its Phase 1/2 Study Using Immucin In Myeloma Patients In The "British Journal Of Hematology" 12/15/2014
Astellas Pharma Inc. (ALPMY) Release: Data Presented From Phase 2 Study Of Enzalutamide In Advanced Androgen-Receptor Positive, Triple-Negative Breast Cancer 12/15/2014
ChemoCentryx, Inc. (CCXI) Announces Positive Results In Phase 2 Diabetic Nephropathy Trial With CCR2 Inhibitor CCX140 12/12/2014
ChemoCentryx, Inc. (CCXI)To Host Conference Call On Friday, December 12, 2014 To Discuss Top-Line Phase 2 Results In Patients With Diabetic Nephropathy With CCX140, An Orally Administered CCR2 Inhibitor 12/12/2014
TWi Pharmaceuticals, Inc. Receives Approval Of Protocol For Its Drug Ac-201 Controlled-Release Tablet, Phase 2 Clinical Trial In Both The United States And Taiwan 12/12/2014
Merck & Co. (MRK),NewLink Genetics Ebola Trial Suspended After Patients Complain Of Joint Pain 12/12/2014
Kamada Ltd. (KMDA) Announces Positive Interim Results From Phase 1/2 Clinical Study Of Its Human Alpha-1 Antitrypsin To Treat Graft-Versus-Host Disease Presented At American Society of Hematology Annual Meeting 12/11/2014
Karyopharm Therapeutics (KPTI) Initiates Third Registration-Directed Clinical Trial Of Oral Selinexor (KPT-330) 12/11/2014
International Breast Cancer Study Group, Breast International Group And Merck & Co. (MRK) Announce Opening Of International PANACEA Study Of Patients With HER2+ Breast Cancer 12/11/2014
Cellceutix (CTIX): Prurisol™ For Psoriasis -- FDA Agrees That Phase 2 Study May Begin 12/11/2014
Neurovance Announces Top-Line Study Results Suggest Lower Abuse Potential For Centanafadine Compared To Stimulants Used For Adult ADHD 12/11/2014
ARCA biopharma Announces Activation Of First Canadian Genetic-AF Clinical Trial Site 12/11/2014
FDA Grants BioMarin Pharmaceutical Inc. (BMRN) Orphan Drug Designation For NAGLU Fusion Protein, BMN 250, For The Treatment Of MPS IIIB (Sanfilippo Syndrome Type B) 12/10/2014
International Breast Cancer Study Group, Breast International Group And Merck & Co. (MRK) Announce Opening Of International PANACEA Study Of Patients With HER2+ Breast Cancer 12/10/2014
Naurex Inc.'s GLYX-13 Demonstrates Robust, Sustained Antidepressant Effects And Excellent Tolerability In Phase 2b Study 12/10/2014
Merck Announces Positive Data Investigating The Use Of Pembrolizumab In Patients With Advanced Triple-Negative Breast Cancer At 2014 San Antonio Breast Cancer Symposium 12/10/2014
Celgene (CELG) Release: Combination Of ISTODAX® (Romidepsin) And Standard CHOP Demonstrates A Complete Response In 51% Of Patients With Peripheral T-Cell Lymphoma 12/10/2014
Marina Biotech, Inc. (MRNA) Reports That Licensee ProNAi Therapeutics, Inc. Presented Interim Phase 2 Data On Its BCL2-Targeting DNAi® Therapeutic At American Society of Hematology 2014 12/10/2014
Ironwood Pharmaceuticals (IRWD) Initiates Phase 2a Clinical Study Of IW-9179 In Diabetic Gastroparesis 12/9/2014
Celgene (CELG) Release: REVLIMID® (Lenalidomide) Single-Agent And Combination Studies In Mantle Cell Lymphoma (MCL) Presented At American Society of Hematology 12/9/2014
OncoSec Medical Inc. Announces New Phase II Trial In Head And Neck Cancer Using ImmunoPulse 12/9/2014
Bristol-Myers Squibb Company (BMY), Merck & Co. (MRK) Drugs Effective In Hodgkin Lymphoma Trials 12/9/2014
Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA (ibrutinib) In Combination With Rituximab Data Shows Positive Benefit-Risk Profile In Hematologic Malignancy 12/9/2014
Amgen (AMGN) Presents Data From Pivotal Phase 2 Study Of BLINCYTO (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia 12/9/2014
Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA (ibrutinib) Data Demonstrates Safety And Durability Of Response At Two-Year Follow-Up In Mantle Cell Lymphoma 12/9/2014
Janssen Research & Development Release: IMBRUVICA (ibrutinib) Long-term Follow-up Data In Patients Living With Relapsed/Refractory Mantle Cell Lymphoma Show Almost Half Alive At Two Years 12/9/2014
Kiadis Pharma Presents Positive Data From A Pre Specified Interim Analysis Of The Phase 2 Clinical Program With Its Lead Product ATIR 12/9/2014
Promedior Presents Positive Phase 2 Data For PRM-151 In Myelofibrosis At American Society of Hematology Annual Meeting 12/9/2014
TG Therapeutics, Inc. (MHA) Release: Data From Phase 2 Clinical Trial Of TG-1101 (Ublituximab) And Ibrutinib Shows Compelling Clinical Activity In Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL) 12/9/2014
Celgene (CELG) Release: New Data In Myelodysplastic Syndromes Presented At The 56th American Society of Hematology Annual Meeting And Exposition 12/9/2014
Isis Pharmaceuticals, Inc. (ISIS) Reports Positive Phase 2 Data For ISIS-FXI Rx For The Prevention Of Venous Thrombosis In Patients Undergoing Total Knee Replacement Surgery 12/8/2014
Merck & Co. (MRK) Announces Positive Data Investigating The Use Of Pembrolizumab In Patients With Classical Hodgkin Lymphoma At American Society of Hematology Annual Meeting 12/8/2014
Amgen (AMGN) Announces New Data From Phase 2 BLINCYTO (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease 12/8/2014
Novartis AG (NVS) Highlights New CTL019 Clinical Data Showing Complete Remissions In Children And Young Adults With Relapsed/Refractory Acute Lymphoblastic Leukemia 12/8/2014
Children's Hospital of Philadelphia Release: Benefits Persist In T Cell Therapy For Children With Relapsed Leukemia 12/8/2014
Pharmacyclics, Inc. (PCYC) Release: IMBRUVICA (ibrutinib) Data Suggests Promise In Multiple Myeloma 12/8/2014
MorphoSys AG And Xencor Publish Final Results From Phase 1/2a Trial Of MOR208 (Xmab5574) In CLL/SLL At Xencor Annual Meeting 12/8/2014
American Society of Hematology Release: New Strategies Boost Healthy Red Blood Cell Production To Target Anemia Across A Range Of Blood Disorders 12/8/2014
American Society of Hematology Release: Novel Combinations Of New And Existing Therapies Yield Promising Results for Leukemia Patients With Poor Prognoses 12/8/2014
AbbVie (ABBV) Presents Results from Phase 2 Study Of Investigational Compound Venetoclax (ABT-199/GDC-0199) In Acute Myelogenous Leukemia At The 56th American Society of Hematology Annual Meeting 12/8/2014
MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) (MSHL) Reports Significant Clinical Activity In Phase 2 Study Of Pracinostat In Front Line Acute Myeloid Leukemia 12/8/2014
Sangamo BioSciences, Inc. (SGMO) Presents New Data At American Society of Hematology Meeting Demonstrating Broad Application Of ZFN Mediated Genome-Editing Approach To Therapeutics For Hemophilia And Lysosomal Storage Disorders 12/8/2014
Phosphagenics Limited (POH.AX) Receives Ethics Approval To Commence Topical Phase 2 TPM®/Oxycodone Patch Trial 12/8/2014
Takeda (TKPYY) Presents Phase 2 Data On Maintenance With Single-Agent Investigational Ixazomib In Patients With Newly Diagnosed Multiple Myeloma 12/8/2014
Orphan Drug Status Granted To Telormedix' Lead Product Vesimune For Bladder Cancer 12/8/2014
Generon (Shanghai) Corporation Ltd. Presents The Global Phase 2 Study Results For F-627 (Benegrastim) At American Society of Hematology 56th Annual Meeting At San Francisco 12/8/2014
Seattle Genetics, Inc. (SGEN) And Takeda (TKPYY) Announce Four-Year Survival Data From ADCETRIS® (Brentuximab Vedotin) Pivotal Trial In Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma At American Society of Hematology Annual Meeting 12/8/2014
Global Blood Therapeutics' GBT440 Demonstrates Ability To Positively Impact Fundamental Sickle Cell Disease (SCD) Processes In Studies Presented At 2014 American Society of Hematology Conference 12/8/2014
Threshold Pharmaceuticals, Inc. (THLD) Release: Encouraging Initial Data From Ongoing Phase 1/2 Trial Of TH-302 Plus Bortezomib (Velcade®) Plus Dexamethasone ("TBorD") In Patients With Relapsed/Refractory Multiple Myeloma Presented At American Society of Hematology Annual Meeting 12/8/2014
Ariad Pharmaceuticals, Inc. (ARIA) Announces Long-Term Safety And Efficacy Data Of Ponatinib From Phase 2 Pace Clinical Trial 12/8/2014
BioLineRx Ltd. Reports Positive Data from Ongoing Phase 2a Study for AML Treatment at American Society of Hematology Conference 12/8/2014
Celgene (CELG) Release: New Data From Luspatercept Phase 2 Clinical Trial In Beta-Thalassemia Presented at the 56th American Society of Hematology Annual Meeting and Exposition 12/8/2014
OncoSec Medical Inc. Reports Positive Top-Line Six-Month Primary Endpoint Data From Phase II Melanoma Trial Of ImmunoPulse Monotherapy 12/5/2014
OncoSec Medical Inc. Says ImmunoPulse Tumor Drug Met Phase II Endpoints 12/5/2014
QLT Inc. (QLTI) Announces Results From Proof-of-Concept Trial With Oral Synthetic Cis-Retinoid (QLT091001) In Adult Subjects With Impaired Dark Adaptation And/Or Impaired Low Luminance Vision 12/5/2014
Cellular Biomedicine Group (CBMG) Releases Positive 48-Week Data From Phase I/2a Clinical Trial For Rejoin(TM) Treatment Of Knee Osteoarthritis (KOA) 12/5/2014
Celldex Therapeutics, Inc. (CLDX) Initiates A Phase 2 Study Of Glembatumumab Vedotin In Patients With Advanced Melanoma 12/5/2014
ProNAi Therapeutics, Inc. Reports Significant Activity And Ongoing Durable Responses In Relapsed Or Refractory Non-Hodgkin's Lymphoma With PNT2258 12/5/2014
CytRx Corporation (CYTR) Receives Written FDA Communication Regarding Partial Clinical Hold For Aldoxorubicin Clinical Trials 12/4/2014
Acetylon Pharmaceuticals Initiates Phase 2 Study Of Ricolinostat (ACY-1215) In Combination With Pomalyst® 12/4/2014
Aerpio Completes Enrollment Of Phase 2 Study Of Tie2 Activator AKB-9778 For The Treatment Of Patients With Diabetic Macular Edema 12/4/2014
Isis Pharmaceuticals, Inc. (ISIS) Release: ISIS-APOCIII Rx Phase 2 Study In Patients With Familial Chylomicronemia Published In The New England Journal of Medicine 12/4/2014
Genmab A/S (GEN.CO) Announces Phase 2 Study Of Daratumumab In Non-Hodgkin's Lymphomas 12/4/2014
Apricus Biosciences (APRI) Announces First Patient Enrolled In Phase 2a Clinical Trial For Rayva In Patients With Raynaud's Phenomenon 12/4/2014
FDA Lifts Clinical Hold On Flexion Therapeutics (FLXN)'s FX006 For Osteoarthritis Pain 12/3/2014
Lpath, Inc. (LPTN) Completes Enrollment In Its Phase 2 Clinical Trial Of iSONEP For Wet Age-Related Macular Degeneration 12/3/2014
Minerva Neurosciences, Inc. (NERV) Announces Completion Of Development And Final Selection Of Once-Daily Dose Formulation Of MIN-101 For Its Schizophrenia Program 12/3/2014
Biothera Release: New Data Strengthens Correlation Between Biomarker And Cancer Immunotherapeutic Imprime PGG 12/2/2014
MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) (MSHL) Completes Enrollment In Phase 2 Study Of Pracinostat In Front Line Acute Myeloid Leukemia 12/2/2014
Xenetic Biosciences Partner Completes Dosing Of Second Cohort In Phase 2a Study Of Erepoxen® In Patients With Chronic Kidney Disease On Dialysis 12/2/2014
Keryx Biopharmaceuticals (KERX) Release: Auryxia (Ferric Citrate) Phase 2 Data Published In The American Journal Of Kidney Disease 12/2/2014
Jade Therapeutics Awarded $725k Phase 2 SBIR Grant From The Jade Therapeutics 12/1/2014
Novartis AG (NVS) Fires Scientist Who Falsified Data In 6 Research Papers 12/1/2014
Momenta Pharmaceuticals, Inc. (MNTA)' Necuparanib Receives Fast Track Designation From The FDA For The Treatment Of Patients With Metastatic Pancreatic Cancer 12/1/2014
Dynavax Technologies Corporation (DVAX) Regains Full Rights To Investigational TLR 7/9 Inhibitor DV1179 Following Expiration Of Collaboration With GlaxoSmithKline (GSK) 12/1/2014
Galmed Pharmaceuticals Completes Analysis Of A Pharmacokinetic Study Of Aramchol In Healthy Volunteers 12/1/2014
Otonomy, Inc. (OTIC) Achieves Patient Enrollment Target In Phase 2b Clinical Trial Of OTO-104 In Meniere's Disease 12/1/2014
OncoMed Pharmaceuticals, Inc. (OMED) Begins Patient Dosing In Phase 2 Clinical Trial of Tarextumab (Anti-Notch 2/3, OMP-59R5) in Small Cell Lung Cancer 12/1/2014
Karyopharm Therapeutics (KPTI) Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission (EC) 12/1/2014
Takeda Pharmaceuticals’s Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation By U.S. FDA For Relapsed Or Refractory Systemic Light-Chain Amyloidosis 12/1/2014
TRACON Pharmaceuticals, Inc. Initiates Randomized Phase 2 Clinical Trial Of TRC105 In Patients With Renal Cell Carcinoma 12/1/2014
New Paper In Journal Of The American Chemical Society Documents Pioneering Discovery Of GalNAc-Conjugated siRNA By Alnylam Pharmaceuticals (ALNY) Scientists 12/1/2014
Data Published By Researchers From Leading Cancer Institutes Show Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Causes Tumor Cytotoxicity Through Previously Unidentified Mechanism 12/1/2014
Clementia Pharmaceuticals Receives Fast Track Designation For Palovarotene For Treatment Of Fibrodysplasia Ossificans Progressiva (FOP) 12/1/2014
Amarantus BioSciences, Inc. Announces Positive Preclinical Data On The Effects Of MANF On Vision In A Model Of Retinitis Pigmentosa 11/25/2014
Afferent Pharmaceuticals Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency By 75% in Chronic Cough Is Published In The Lancet 11/25/2014
Milestone Pharmaceuticals Announces Positive Phase 1 Data For MSP-2017; Supports Advancement Into Phase 2 In PSVT Patients 11/24/2014
Synthetic Biologics, Inc. (SYN) Safe-To-Proceed Under IND To Initiate Clinical Trials Of SYN-004 For The Prevention C. Difficile Infection 11/24/2014
Transition Therapeutics Inc. (TTH.TO)' ELND005 Showed No Prolongation Of QT Interval 11/24/2014
The Journal of Clinical Endocrinology & Metabolism Publishes Radius Health's Phase 2 Study Of The Investigational Drug Abaloparatide In Postmenopausal Women With Osteoporosis 11/24/2014
Genmab, Inc. (GEN.CO) Announces Phase 2 Study Of Daratumumab In Smoldering Multiple Myeloma 11/24/2014
Sunesis Pharmaceuticals, Inc. (SNSS) Announces Publication Of REVEAL-1 Trial Results In The British Journal Of Haematology 11/24/2014
Xenetic Biosciences Partner Completes First Patient Cohort In Phase 2 Study With MyeloXen™ For Multiple Sclerosis 11/21/2014
University of Pennsylvania Doses First Patient In Phase IIa Clinical Trial Using CardioCell’s Stem Cell Therapy To Treat Chronic Heart Failure (HF) Due To Non-Ischemic Cardiomyopathy 11/21/2014
Proteo Inc. (PTEO.OB)/Proteo Biotech AG (PTEO.OB): Final Analysis Of The Phase II Clinical Study On Elafin In Coronary Artery Bypass Surgery Completed 11/21/2014
Clementia Pharmaceuticals Receives European Medicines Agency Orphan Medicinal Product Designation For Palovarotene For The Treatment Of Fibrodysplasia Ossificans Progressiva 11/21/2014
BioSpecifics Technologies Corporation (BSTC) Announces New Data On XIAFLEX For Peyronie's Disease Presented At SMSNA Scientific Meeting 11/21/2014
Intra-Cellular Therapies, Inc. Announces Additional Results From Phase I/2 Clinical Trial For ITI-007 In Healthy Geriatric Subjects And Patients With Dementia 11/21/2014
ChemoCentryx, Inc. (CCXI)'s CCX168, An Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation In Atypical Hemolytic Uremic Syndrome Treatment By The FDA 11/21/2014
Immunomedics, Inc. (IMMU) Announces Orphan Drug Designation For Veltuzumab For The Treatment Of Pemphigus 11/21/2014
NeoStem, Inc. Provides Further Information Regarding The Design Of The Phase 2 PreSERVE AMI Clinical Trial 11/21/2014
Clovis Oncology (CLVS) Release: Initial Data From Ongoing Phase 2 ARIEL2 Study Of Rucaparib In Ovarian Cancer Demonstrate Encouraging Clinical Activity And Safety In Both BRCA Mutant And Brcaness Patients 11/20/2014
Neurotrope Announces Last Patient Dosed In Phase 2a Clinical Trial Of Bryostatin-1 For Alzheimer's Disease 11/20/2014
Transition Therapeutics Inc. (TTH.TO) Announces Results From ELND005 Clinical Study In Adults With Down Syndrome 11/20/2014
St. Jude Children's Research Hospital Release: Gene Therapy Provides Safe, Long-Term Relief For Patients With Severe Hemophilia B 11/20/2014
DBV Technologies Initiates Phase I/2 Clinical Trial With Viaskin Milk For The Treatment Of Children With Cow's Milk Allergy 11/20/2014
PRANA Biotechnology (PRAN) Release: The Lancet Neurology Publishes Prana's Huntington Disease Trial 11/20/2014
Autifony Therapeutics Announces Initiation Of Phase 2a Study For First-In-Class Drug To Treat Tinnitus 11/20/2014
Neurotrope Announces Last Patient Dosed In Phase 2a Clinical Trial Of Bryostatin-1 For Alzheimer’s Disease 11/20/2014
Auxilium Pharmaceuticals (AUXL) Presents XIAFLEX For Peyronie's Disease Data At SMSNA Scientific Meeting 11/20/2014
Auxilium Pharmaceuticals (AUXL) Presents STENDRA Data At SMSNA Scientific Meeting 11/20/2014
MabVax Therapeutics, Inc. And Memorial Sloan-Kettering Cancer Center Report On Potential Use Of Dual-Labeled Antibody To Detect And Guide Surgical Removal Of Pancreatic Cancer 11/19/2014
NeoStem, Inc.'s Stem Cell Therapy Fails Mid-Stage Heart Attack Study 11/19/2014
Cynapsus Therapeutics (CYNAF) Announces Positive Top-Line Results From CTH-105 Phase 2 Study Of APL-130277 For The Treatment Of OFF Episodes In Patients With Parkinson's Disease 11/19/2014
Sunesis Pharmaceuticals, Inc. (SNSS) Announces Publication Of Vosaroxin Phase 1b/2 AML Trial Results In Haematologica 11/19/2014
Bio Blast Pharma Receives Orphan Drug Designation From U.S. FDA For Cabaletta For The Treatment Of Spinocerebellar Ataxia Type 3 11/19/2014
Synergy Pharmaceuticals Announces Positive Results Of SP-333 Phase 2 Trial In Patients With Opioid-Induced Constipation 11/19/2014
BIND Therapeutics (BIND) Presents Positive Phase 2 Results Highlighting Potential Of BIND-014 As Novel Anti-Cancer Treatment At Q3W Dosing Schedule For Patients With Non-Small Cell Lung Cancer At 26th EORTC-NCI-AACR Annual Symposium 11/19/2014
Tokai Pharmaceuticals (TKAI) Presents Updated Interim Galeterone ARMOR2 Data Showing Activity In Patients With Castration-Resistant Prostate Cancer (CRPC) Including Those Showing A Variant Form Of Prostate Cancer Resistant To Hormone Therapy 11/19/2014
PTC Therapeutics, Inc. (PTCT) Release: Spinal Muscular Atrophy Program Enters Phase 1b/2a Trial In Patients With SMA 11/19/2014
Amgen (AMGN) Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels 11/19/2014
VGTI Florida To Collaborate With TapImmune Inc. (TPIV) To Advance Targeted Breast And Ovarian Cancer Vaccines Into Phase 2 Clinical Trials 11/19/2014
Omni Bio Pharmaceutical Announces Phase 1/2 Clinical Data Of AAT In Myocardial Infarction At American Heart Association Scientific Session 11/19/2014
Omeros Corporation (OMER) Release: OMS721 Inhibits Thrombus Formation In Sera from aHUS Patients 11/19/2014
UPDATE: Bionor Pharma ASA Announces That The Combination Of Vacc-4x + Revlimid(R) Is Well Tolerated And Increases CD4 Counts In People Living With HIV 11/19/2014
NeoStem, Inc. Announces Initial Positive Data From Phase 2 Preserve AMI Clinical Trial 11/18/2014
Sarepta Therapeutics (SRPT) Announces First Patient Dosed In Confirmatory Study Of Eteplirsen In Ambulant Patients With Duchenne Muscular Dystrophy 11/18/2014
Juventas Therapeutics, Inc. Presents Phase 2 Data At American Heart Association Scientific Sessions That Shows JVS-100 Is Safe, Potentially Effective In Patients With Critical Limb Ischemia 11/18/2014
Innovative Med Concepts, LLC Release: Novel Fibromyalgia Treatment Shows Promise In Study 11/18/2014
Juno Therapeutics's JCAR015 Leukemia T Cell Therapy Granted Orphan Drug Designation By FDA 11/18/2014
ObsEva Announces The Initiation Of A Pivotal Phase 2 Study To Evaluate OBE001 For Improving Embryo Implantation And Clinical Pregnancy Rate In Women Undergoing IVF/ICSI 11/18/2014
Galena Biopharma  (GALE) Completes Enrollment In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial 11/18/2014
Levolta Pharmaceuticals Presents Phase 2 Study Results For Potential Osteoarthritis Therapy At American College of Rheumatology Annual Meeting 11/18/2014
Bionor Pharma ASA Announces That The Combination Of Vacc-4x + Revlimid® Is Safe And Increases CD4 Counts In People Living With HIV 11/18/2014
Trevena, Inc. (TRVN) Announces Positive Top-Line Results From Phase 2a/b Study Of TRV130 In Acute Postoperative Pain 11/18/2014
Merck & Co. (MRK) Announces Positive Study Investigating The Use Of KEYTRUDA® (pembrolizumab) Compared To Chemotherapy In Patients With Ipilimumab-Refractory Advanced Melanoma 11/17/2014
Wilson Therapeutics Announces Start Of Phase 2 Study To Evaluate The Efficacy And Safety Of WTX101 In Newly Diagnosed Wilson Disease Patients 11/17/2014
NeuroSigma, Inc. Announces Top-Line Findings Of University of California, Los Angeles (UCLA) Phase 2 Clinical Trial Of eTNS For The Treatment Of Depression 11/17/2014
OrthoTrophix Completed Patient Treatments In Part A Of The Phase 2 Clinical Trial Of A New Cartilage Repair Therapeutic For Knee Osteoarthritis And Initiated Patient Enrollment For Part B 11/17/2014
AbbVie (ABBV) Presents Results From Study Of ABT-414 In Patients With Glioblastoma Multiforme At The 19th Annual Scientific Meeting And Education Day Of The Society For Neuro-Oncology 11/17/2014
Alder Biopharmaceuticals Inc. Release: Data From Phase 2b Clinical Trial Of Clazakizumab, An Anti-IL-6 Monoclonal Antibody For The Treatment Of Active Psoriatic Arthritis, To Be Presented At The American College of Rheumatology Annual Meeting 11/17/2014
MedImmune (AZN) Presents Promising New Data In Systemic Lupus At American College of Rheumatology Meeting 11/17/2014
MedImmune (AZN) Presents Positive Phase 2b Data For Mavrilimumab In Rheumatoid Arthritis At American College of Rheumatology Annual Meeting 11/17/2014
DelMar Pharmaceuticals' Promising New Data Support The Potential Of VAL-083 To Meet Significant Unmet Medical Needs In The Treatment Of Glioblastoma Multiforme 11/17/2014
Novavax, Inc. (NVAX) Initiates Phase 2 Clinical Trial Of Quadrivalent Seasonal Influenza VLP 11/17/2014
ChemoCentryx, Inc. (CCXI)'s Orally Administered C5aR Inhibitor CCX168 Shows Benefit In Non-Renal ANCA Vasculitis Disease Activity, In Addition To Previously Shown Kidney Disease Improvements 11/17/2014
Ardelyx Inc. (ARDX)'s Tenapanor Reduces Phosphorus Absorption And Protects Against Vascular Calcification In Preclinical In Vivo Model Of Chronic Kidney Disease 11/17/2014